|
[1] Lunn JS, Sakowski SA, Hur J, et al. Stem cell technology for neurodegenerative diseases
[J]. Ann Neurol, 2011, 70(3): 353-361.
[2] Soykan I, Lin Z, Bennett JP, et al. Gastric myoelectrical activity in patients with Parkinson's disease (Evidence of a Primary Gastric Abnormality)
[J]. Dig Dis Sci, 1999, 44(5): 927-931.
[3] Cersosimo MG, Benarroch EE. Pathological correlates of gastrointes- tinal dysfunction in Parkinson's disease
[J]. Neurobiol Dis, 2012, 46(3): 559-564.
[4] Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease
[J]. Parkinsonism Relat Disord, 2011,17(1): 10-15.
[5] Salawu FK, Danburam A, Olokoba AB. Non-motor symptoms of Parkinson's disease: diagnosis and management
[J]. Niger J Med, 2010, 19(2):126-131.
[6] Takahashi M. Role of the SDF-1/CXCR4 system in myocardial infarction
[J]. Circ J, 2010, 74(3): 418-423.
[7] Gazitt Y. Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-speci?c antibodies
[J]. Leukemia, 2004, 18(1): 1-10.
[8] ernández-López C, Varas A, Sacedón R, et al. The CXCL12/CXCR4 pair in aged human thymus
[J]. Neuroimmunomodulation, 2010,17(3): 217-220.
[9] Gassmann P, Haier J, Schlüter K, et al. CXCR4 regulates tumor cell extravasation in vivo
[J]. Neoplasia, 2009, 11(7): 651-661.
[10]Shimoji M, Pagan F, Healton EB, et al. CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease
[J]. Neurotox Res, 2009,16(3): 318-328.
[11]Zeevalk GD, Razmpour R, Bernard LP. Glutathione and Parkinson's disease: is this the elephant in the room
[J]? Biomed Pharmacother, 2008, 62(4):236-249.
[12]Jenner P. Oxidative stress and Parkinson's disease
[J]. Handb Clin Neurol, 2007, 83:507-520.
[13]Cuadrado A, Rojo A I. Heme oxygenase-1 as a therapeutic target in neurodegenerative diseases and brain infections
[J]. Curr Pharm Des, 2008, 14(5):429-442.
[14]Chao Y, Wong SC, Tan EK. Evidence of inflammatory system involvement in Parkinson's disease
[J]. Biomed Res Int, 2014:308654.
[15]Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with
[11C](R)-PK11195 PET in idiopathic Parkinson's disease
[J]. Neurobiol Dis, 2006, 21(2):404-412.
[16]Tran PB, Ren D, Veldhouse TJ, et al. Chemokine receptors are expressed widely by embryonic and adult neural progenitor cells
[J]. J Neurosci Res, 2004, 76(1): 20-34.
[17]Carbajal KS, Schaumburg C, Strieter R, et al. Migration of engrafted neural stem cells is mediated by CXCL12 signaling through CXCR4 in a viral model of multiple sclerosis
[J]. Proc Nati Acad Sci U S A, 2010, 107(24): 11068-11073.
[18]McCandless EE, Budde M, Lees JR, et al. IL-1R signaling within the central nervous system regulates CXCL12 expression at the blood-brain barrier and disease severity during experimental autoimmune encephalomyelitis
[J]. J Immunol, 2009, 183(1):613-620.
[19]McCandless EE, Piccio L, Woerner BM, et al. Pathological expression of CXCL12 at the blood -brain barrier correlates with severity of multiple sclerosis
[J]. Am J Pathol , 2008, 172(3):799-808.
[20]Mocchetti I, Bachis A, Masliah E. Chemokine receptors and neurotrophic factors: potential therapy against aids dementia
[J]? J Neurosci Res, 2008, 86(2):243-255.
[21]Robin AM, Zhang ZG, Wang L, et al. Stromal cell derived factor-1 alpha mediates neural progenitor cell motility after focal cerebral ischemia
[J] . J Cereb BloodFlow Metab, 2006, 26(1):125- 134.
[22]Bachis A, Mocchetti I. The chemokine receptor CXCR4 and not the N-methyl-D-aspartate receptor mediates gp120 neurotoxicity in cerebellar granule cells
[J]. J Neurosci Res, 2004, 75(1):75-82.
[23]Corasaniti MT , Piccirilli S, Pao letti A, et al. Evidence that the HIV-1 coat protein gp120 causes neuronal apoptosis in the neocortex of rat via a mechanism involving CXCR4 chemokine receptor
[J]. Neurosci Lett, 2001, 312(2): 67- 70.
|
